2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Polycythemia Vera
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Carcinoma, Hepatocellular
6
Thrombocythemia, Essential
5
Neoplasms
3
Melanoma
3
Skin Neoplasms
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Leukemia
2
Hepatitis C, Chronic
2
Carcinoma, Squamous Cell
2
Brain Neoplasms
2
Solid Cancers
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Neoplasm of Uncertain Malignant Potential
1
Liver Cirrhosis
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Influenza, Human
1
Infections
1
Hepatitis D
1
Hepatitis C
1
Hepatitis B, Chronic
1
Hepatitis B
1
Hemangiosarcoma
1
Interventions
Cyclophosphamide
62
fludarabine phosphate
55
Peripheral Blood Stem Cell Transplantation
44
ruxolitinib
41
Tacrolimus
41
Busulfan
40
Mycophenolic Acid
36
Whole-Body Irradiation
32
Antilymphocyte Serum
29
Methotrexate
27
Cyclosporine
27
fludarabine
24
Melphalan
19
Filgrastim
19
Radiotherapy
15
Methylprednisolone
13
thymoglobulin
12
Stem Cell Transplantation
12
Etoposide
12
Cord Blood Stem Cell Transplantation
12
Azacitidine
12
Sirolimus
11
Flow Cytometry
10
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
10
Psychiatric Rehabilitation
9
Decitabine
9
Specimen Handling
8
Prednisone
8
Cytarabine
8
navitoclax
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
peginterferon alfa-2a
×
Clear all
NCT01387763
2022-04-27
DALIAH
Odense University Hospital
Phase 3
Completed
202 enrolled